Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


Breast Cancer Specialist Presents Positive Results for Triple-Negative Breast Cancer Presurgery Chemotherapy Benefits
A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.

Adding cediranib to chemo improves progression-free survival for meta or recurrent cervical cancer
For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

Cancer-fighting cocktail demonstrates promising results as new treatment for advanced cervical cancer
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

Cheaper alternative to licensed drug for treating eye disease has similar side-effects
Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

Women & Infants Breast Cancer Specialist Reports Advance in Treatment of Triple-Negative Breast Cancer
William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women.

Hijacking the brain's blood supply: Tumor discovery could aid treatment
Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Researcher discovers ovarian cancer treatment
Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.
More Bevacizumab Current Events and Bevacizumab News Articles

Pathology of the Ovary, Fallopian Tube and Peritoneum (Essentials of Diagnostic Gynecological Pathology)

Pathology of the Ovary, Fallopian Tube and Peritoneum (Essentials of Diagnostic Gynecological Pathology)
by Nafisa Wilkinson (Editor)


As the second volume in the Essentials of Diagnostic Gynecological Pathology series sponsored by the British Association of Gynecological Pathologists, Pathology of the Ovary, Fallopian Tube and Peritoneum is one of the very few dealing wholly with this subject. Pathology of the Ovary, Fallopian Tube and Peritoneum introduces the topic with a discussion of the anatomy, development, histology and normal function of the ovary, followed by chapters on non-neoplastic disorders of the ovary; surgery and medical management of ovarian cancer; and the use of imaging, frozen sections and cytology in ovarian pathology. The book then goes on to describe specific disorders of the ovary, fallopian tube and peritoneum in detail, and finishes with a chapter on specimen cut-up.  Pathology of the Ovary,...

Cancer Immunotherapy: Paradigms, Practice and Promise

Cancer Immunotherapy: Paradigms, Practice and Promise
by Tyler J. Curiel (Editor)


This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity.

Advances in Surgical Pathology: Colorectal Carcinoma and Tumors of the Vermiform Appendix

Advances in Surgical Pathology: Colorectal Carcinoma and Tumors of the Vermiform Appendix
by Rhonda Yantiss MD (Author)


Advances in Surgical Pathology: Colorectal Carcinoma and Tumors of the Vermiform Appendix, a volume in the Advances in Surgical Pathology series, features chapters on current and impending changes in the field with an emphasis on practical issues, recent developments, and emerging concepts.Created as a quick review to be used during pathologic evaluation of cancer specimens from the lower gastrointestinal tract, this book contains the latest information regarding emerging endoscopic techniques that aid in tumor classification and staging, mechanisms of pathogenesis, and clinical management. It combines gross and microscopic images and user-friendly tables for quick reference with a succinct, comprehensive review of issues important to management of patients with colorectal carcinoma. Not...

Neuro-Oncology Part I, Volume 104: Handbook of Clinical Neurology (Series Editors: Aminoff, Boller and Swaab)

Neuro-Oncology Part I, Volume 104: Handbook of Clinical Neurology (Series Editors: Aminoff, Boller and Swaab)
by Wolfgang Grisold (Editor), Riccardo Soffietti (Editor)


Handbook of Clinical Neurology: Neuro-Oncology, Part I summarizes the present state of scientific and clinical knowledge in the field of neuro-oncology, including information related to diagnostic techniques such as imaging, along with immunology, molecular biology, and clinical aspects of tumors. Management and new therapeutic strategies for tumors, including gene therapy and molecularly targeted treatments, are also covered.
Divided into eight sections encompassing 61 chapters, the book begins with an overview of the basic principles of tumors, including the epidemiology of primary central nervous system tumors, angiogenesis and invasion in cancer, the link between blood-brain barrier and brain edema, and the role of stem cells in gliomas. It proceeds with a discussion of diagnostic...

Management of Castration Resistant Prostate Cancer (Current Clinical Urology)

Management of Castration Resistant Prostate Cancer (Current Clinical Urology)
by Fred Saad (Editor), Mario A. Eisenberger (Editor)


This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine.As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this...

Glioma Cell Biology

Glioma Cell Biology
by Aleksi Sedo (Editor), Rolf Mentlein (Editor)


Gliomas are fatal diseases, but also represent good models for tumor research with the aim to eventually discover new and appropriate therapeutics against this disease. Glioma experimental research models are of help to investigate tumorigenesis (tumor stem cell theory versus "classical" opinions), tumor angiogenesis (since they are highly vascularized) and tumor invasion (since they grow without limits). In addition, they have a very special microenvironment (the brain) and limited tumor stroma cells (mainly microglia and endothelial cells). This book addresses the molecular mechanisms of the various tumor stages, describes the interaction with the tumor microenvironment and furthermore depicts experimental models for Glioma research and future therapeutic concepts. The book is composed...

Intraperitoneal Therapy for Ovarian Cancer

Intraperitoneal Therapy for Ovarian Cancer
by David Alberts (Editor), Mary C. Clouser (Editor), Lisa M. Hess (Editor)


Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Chemotherapy have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing...

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

  Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article): An article from: Family Practice News
by Jeff Evans (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2003. The length of the article is 1131 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article)
Author: Jeff Evans
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2003
Publisher: International Medical News Group
Volume: 33 Issue: 17 Page: 42(1)

Article Type: Brief Article

Distributed by Thomson...

  Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds): An article from: Internal Medicine News
by Jeff Evans (Author)


This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 318 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds)
Author: Jeff Evans
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 19 Page: 26(1)

Distributed by Thomson...

© 2015 BrightSurf.com